Compare IMXI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | CERS |
|---|---|---|
| Founded | 1994 | 1991 |
| Country | United States | United States |
| Employees | N/A | 345 |
| Industry | Retail: Computer Software & Peripheral Equipment | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 534.0M |
| IPO Year | 2016 | 1996 |
| Metric | IMXI | CERS |
|---|---|---|
| Price | $11.41 | $2.61 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 376.0K | ★ 1.4M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $319,601,000.00 | $51,326,000.00 |
| Revenue This Year | $0.83 | $19.95 |
| Revenue Next Year | $1.49 | $8.84 |
| P/E Ratio | $80.67 | ★ N/A |
| Revenue Growth | 16.68 | ★ 30.68 |
| 52 Week Low | $11.15 | $1.38 |
| 52 Week High | $15.95 | $3.47 |
| Indicator | IMXI | CERS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.